Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis

References

• Ryu JH, Moua T, Daniels CE, et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014;89:1130–1142.
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. European Respiratory Review. 2012;21:355–361.
   PubMedGoogle Scholar
• Harari S, Madotto F, Caminati A, et al. Epidemiology of idiopathic pulmonary fibrosis in Northern Italy. Ciccozzi M, editor. PLoS One. 2016;11:e0147072.
   PubMed Web of Science ®Google Scholar
• Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol. 2000;152:307–315.
   PubMed Web of Science ®Google Scholar
• Michaelson JE, Aguayo SM, Roman J. Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management. Chest. 2000;118:788–794.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Diagnosis and management of suspected idiopathic pulmonary fibrosis: idiopathic pulmonary fibrosis [Internet]. Natl Inst Heal Care Excell Clin Guidel. 2013.
   Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170:904–910.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
   PubMed Web of Science ®Google Scholar
• Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011;17:348–354.
   PubMed Web of Science ®Google Scholar
• Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63:v1–58.
   PubMed Web of Science ®Google Scholar
• Sheikh SI, Hayes D, Kirkby SE, et al. Age-dependent gender disparities in post lung transplant survival among patients with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2017;103:441–446.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769.
   PubMed Web of Science ®Google Scholar
• Rochwerg B, Neupane B, Zhang Y, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. 2016;14:18.
   PubMed Web of Science ®Google Scholar
• Fleetwood K, McCool R, Glanville J, et al. Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments. J Manag Care Spec Pharm. 2017;23:S5–S16.
   PubMedGoogle Scholar
• Canestaro WJ, Forrester SH, Raghu G, et al. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest. 2016;149:756–766.
   PubMed Web of Science ®Google Scholar
• Loveman E, Copley VR, Scott DA, et al. Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis. BMC Pulm Med. 2015;15:37.
   PubMed Web of Science ®Google Scholar
• Rinciog C, Watkins M, Chang S, et al. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. Pharmacoeconomics. 2017;35:479–491.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
   PubMed Web of Science ®Google Scholar
• Bois R. d, Weycker D, Albera C, et al. Six-Minute-Walk Test in Idiopathic Pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183:1231–1237.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG SJ (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). The Cochrane Collaboration, 2011. Cochrane Handb Syst Rev Interv Version 510 (updated March 2011). (Available from handbook.cochrane.org.).
   Google Scholar
• Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Zhao J, Valkenhoef GV, Brock BD, et al. ADDIS: an automated way to do network meta-analysis. 2012;1–17.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. National Institute for Health and Care Excellence (NICE); 2014.
   Google Scholar
• Mills EJ, Ioannidis JPA, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308:1246.
   PubMed Web of Science ®Google Scholar
• Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis. 2003;62:316–321.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. In: Cates CJ, editor. Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009. p. CD007695.
   Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434–455.
   Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–171.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829.
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
   PubMed Web of Science ®Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–1392.
   PubMed Web of Science ®Google Scholar
• Huang H, Dai HP, Kang J, et al. Double-blind randomized trial of pirfenidone in Chinese idiopathic pulmonary fibrosis patients. Medicine (Baltimore). 2015;94:e1600.
   PubMed Web of Science ®Google Scholar
• Yoon HY, Park S, Kim DS, et al. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res. 2018;19:203.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Fell DC, Huggins JT, et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018;52:1800230.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the injourney trial. Am J Respir Crit Care Med. 2018;197:356–363.
   PubMed Web of Science ®Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7:60–68.
   PubMed Web of Science ®Google Scholar